Review



brd2  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology brd2
    D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of <t>BRD2,</t> BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).
    Brd2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/brd2/product/Santa Cruz Biotechnology
    Average 92 stars, based on 27 article reviews
    brd2 - by Bioz Stars, 2026-06
    92/100 stars

    Images

    1) Product Images from "BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis"

    Article Title: BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis

    Journal: iScience

    doi: 10.1016/j.isci.2025.114526

    D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of BRD2, BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).
    Figure Legend Snippet: D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of BRD2, BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).

    Techniques Used: Control, In Vitro, Expressing, Ubiquitin Proteomics, Knockdown, Western Blot, Binding Assay



    Similar Products

    gene exp brd2 hs01121986 g1  (Thermo Fisher)
    86
    Thermo Fisher gene exp brd2 hs01121986 g1
    Gene Exp Brd2 Hs01121986 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp brd2 hs01121986 g1/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    gene exp brd2 hs01121986 g1 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    anti brd2  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc anti brd2
    Anti Brd2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti brd2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    anti brd2 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    brd2 sirna  (Sangon Biotech)
    86
    Sangon Biotech brd2 sirna
    Brd2 Sirna, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/brd2 sirna/product/Sangon Biotech
    Average 86 stars, based on 1 article reviews
    brd2 sirna - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    antibodies against brd2  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc antibodies against brd2
    Antibodies Against Brd2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against brd2/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    antibodies against brd2 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    brd2  (Santa Cruz Biotechnology)
    92
    Santa Cruz Biotechnology brd2
    D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of <t>BRD2,</t> BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).
    Brd2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/brd2/product/Santa Cruz Biotechnology
    Average 92 stars, based on 1 article reviews
    brd2 - by Bioz Stars, 2026-06
    92/100 stars
    		  Buy from Supplier
    514103 rrid ab 3720459  (Santa Cruz Biotechnology)
    92
    Santa Cruz Biotechnology 514103 rrid ab 3720459
    D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of <t>BRD2,</t> BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).
    514103 Rrid Ab 3720459, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/514103 rrid ab 3720459/product/Santa Cruz Biotechnology
    Average 92 stars, based on 1 article reviews
    514103 rrid ab 3720459 - by Bioz Stars, 2026-06
    92/100 stars
    		  Buy from Supplier
    anti brd2 antibody  (Signalway Antibody)
    86
    Signalway Antibody anti brd2 antibody
    D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of <t>BRD2,</t> BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).
    Anti Brd2 Antibody, supplied by Signalway Antibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti brd2 antibody/product/Signalway Antibody
    Average 86 stars, based on 1 article reviews
    anti brd2 antibody - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of BRD2, BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).

    Journal: iScience

    Article Title: BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis

    doi: 10.1016/j.isci.2025.114526

    Figure Lengend Snippet: D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of BRD2, BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).

    Article Snippet: BRD2 , Santa Cruz , sc-514103; RRID:AB_3720459.

    Techniques: Control, In Vitro, Expressing, Ubiquitin Proteomics, Knockdown, Western Blot, Binding Assay